for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

600196.SS

Latest Trade

70.35CNY

Change

1.55(+2.25%)

Volume

57,636,236

Today's Range

65.10

 - 

71.16

52 Week Range

36.67

 - 

82.74

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
68.80
Open
67.40
Volume
57,636,236
3M AVG Volume
1,360.38
Today's High
71.16
Today's Low
65.10
52 Week High
82.74
52 Week Low
36.67
Shares Out (MIL)
2,562.90
Market Cap (MIL)
164,780.10
Forward P/E
39.98
Dividend (Yield %)
0.63

Next Event

Q2 2021 Shanghai Fosun Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

More

Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement

JPMorgan Chase & Co's Long Position In Shanghai Fosun Pharma Falls To 4.69% - HKEX Filing

Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Building A, No. 1289 Yishan Road

SHANGHAI, SHA

200233

China

+86.21.33987870

http://www.fosunpharma.com

Executive Leadership

Yifang Wu

Chairman of the Board, Chief Executive Officer, Executive Director

Yuqing Chen

Co-President

Dongming Li

Co-President

Kexin Wang

Co-President

Xiaohui Guan

Chief Financial Officer, Executive President

Key Stats

1.92 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

24.9K

2019

28.6K

2020

30.3K

2021(E)

36.6K
EPS (CNY)

2018

1.070

2019

1.300

2020

1.430

2021(E)

1.721
Price To Earnings (TTM)
45.18
Price To Sales (TTM)
5.07
Price To Book (MRQ)
4.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.41
LT Debt To Equity (MRQ)
26.26
Return on Investment (TTM)
8.15
Return on Equity (TTM)
5.20

Latest News

Latest News

Fosun-BioNTech COVID-19 vaccine completes China regulator review - media

Chinese regulators have completed an expert review of a COVID-19 mRNA vaccine developed by Germany's BioNTech and Fosun Pharma and the shot is in the administration review stage, Caixin reported, citing the Chinese company.

Chinese firm says to provide Taiwan with 10 mln COVID-19 vaccines

China's Shanghai Fosun Pharmaceutical Group Co Ltd, the Chinese sales agent for Germany's BioNTech SE, said on Sunday it had signed a deal to provide 10 million doses of COVID-19 vaccine to Taiwan.

Fosun Pharma to provide factory with annual capacity of 1 billion doses of BioNTech's COVID-19 vaccine

China's Shanghai Fosun Pharmaceutical said its subsidiary has agreed to provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine developed by BioNTech.

Fosun Pharma's subsidiary, BioNTech to set up JV for COVID-19 vaccine production

China's Shanghai Fosun Pharmaceutical said on Sunday its subsidiary had agreed to set up a joint venture with BioNTech for the manufacture and commercialisation of the German firm's COVID-19 vaccine.

Hong Kong says initial investigation of BioNTech vaccines shows no 'obvious systemic factors'

Hong Kong's government said an initial investigation by Germany's BioNTech and Fosun Industrial into its coronavirus vaccine did not show any "obvious systemic factors" during packaging after use of the vaccine was suspended in the city and neighbouring Macau this week.

Hong Kong expects findings of inquiry into BioNTech vaccine packaging defects next week: SCMP

Hong Kong expects the preliminary findings of an investigation into packaging defects of the COVID-19 vaccine developed by Germany's BioNTech SE as soon as next week, the South China Morning Post reported on Saturday, citing Secretary for the Civil Service Patrick Nip (https...

Hong Kong formally approves Fosun Pharma-BioNTech vaccine

Hong Kong has formally approved use of the Fosun Pharma-BioNTech vaccine, the city government said on Monday, the first COVID-19 vaccine to be accepted in the Asian financial hub.

China's Fosun plans plant to make BioNTech's COVID-19 vaccine -Caixin

Shanghai Fosun Pharmaceutical Group is planning a facility in China to produce the COVID-19 vaccine developed by Germany's BioNTech, financial magazine Caixin reported on Wednesday.

China's Fosun to set up JV with BioNTech to make COVID-19 vaccines-Caixin

Shanghai Fosun Pharmaceutical Group will set up a joint venture with Germany's BioNTech to produce COVID-19 vaccines in China, financial magazine Caixin reported on Wednesday.

Fosun Pharma to buy 100 million doses of BioNTech's COVID-19 vaccine for mainland China

Shanghai Fosun Pharmaceutical Group Co Ltd on Wednesday said it will buy at least 100 million doses of a COVID-19 vaccine from Germany's BioNTech SE for use in mainland China next year, if the vaccine receives approval.

China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine

Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.

China's Fosun to seek approval for BioNTech's COVID-19 second vaccine, ends trials on first

BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm's coronavirus vaccine candidate that has completed early-stage trials in China, an executive said.

Germany grants BioNTech, CureVac $745 million to speed up COVID-19 vaccine work

Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.

BioNTech, China's Fosun to potentially supply 10 million doses of COVID-19 vaccine

German drug developer BioNTech SE on Thursday announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd to supply 10 million doses of their COVID-19 vaccine candidate to Hong Kong and Macau.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up